Although a randomized phase 3 study by Fenaux et al (2009) [33] indicated that HMAs conferred an overall survival benefit compared with supportive care, HMAs did not prolong the OS of MDS patients with TET2 mutations compared to those without in studies [27, 30]. The gene discussed is TET2; the disease is myelodysplastic syndrome.